Engineered Bacteria Secreting IL-22 for Intestinal Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation-induced intestinal damage, such as those caused by irradiation therapy or accidents, are inadequate in preventing or treating the severe gastrointestinal syndrome that leads to intestinal cell loss and sepsis, with existing mitigators showing limited effectiveness in improving survival rates.
Innovation Solution
Administration of gastrointestinal tract bacteria engineered to encode and secrete IL-22 or IFN-β, specifically using strains like Lactobacillus reuteri or Escherichia coli, which are orally administered to treat or prevent irradiation-induced intestinal damage by promoting survival and preserving intestinal stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional irradiation mitigators are administered, then some protection against intestinal damage is provided, but survival rates remain limited and intestinal cell loss continues
Solution Approach 1:
The patent uses engineered bacteria as living intermediaries that deliver protective cytokines (IL-22 and IFN-β) directly to the intestinal tissue. These bacteria act as mediators between the administered treatment and the target intestinal cells, providing sustained local protection that small molecule mitigators cannot achieve. The bacteria colonize the gut and continuously produce protective factors at the site of injury.
Solution Approach 2:
The engineered bacteria are designed to autonomously produce and secrete protective cytokines (IL-22 and IFN-β) once administered. The bacteria self-replicate and self-sustain the protective effect without requiring continuous external administration of mitigators. This self-service capability provides prolonged protection and improves survival rates compared to traditional mitigators that require repeated dosing.
2Reliability
If high doses of irradiation are administered for cancer treatment, then tumor control is improved, but severe gastrointestinal syndrome and intestinal damage occur
Solution Approach 1:
The patent applies preliminary anti-action by administering engineered bacteria that produce protective cytokines before or during irradiation treatment. The IL-22 and IFN-β produced by the bacteria preemptively protect intestinal crypt cells and stem cells from radiation-induced damage, counteracting the harmful effects before they can cause severe gastrointestinal syndrome. This allows higher irradiation doses to be administered safely.
Solution Approach 2:
The patent converts the harmful radiation effect into a beneficial outcome by using the same irradiation that damages intestinal cells to selectively eliminate competing gut bacteria, making space for the engineered protective bacteria to colonize. The radiation-induced bacterial vacuum is filled by the beneficial engineered strains that produce protective cytokines, turning the harmful radiation effect into an opportunity for establishing protective microbiota.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of IL-22 or IFN-β secreting bacteria significantly improves survival rates and mitigates intestinal damage by restoring critical intestinal cells and reducing inflammation, demonstrating a more effective treatment than traditional irradiation mitigators alone.
Implementation Method 1
the bacterium comprises a vector that comprises a polynucleotide encoding IL-22 and/or IFN-β, or a functional fragment thereof
Implementation Method 2
reducing inflammation, demonstrating a more effective treatment than traditional irradiation mitigators alone
Data Source
AI summary
Disclosed herein are gastrointestinal tract (G1) bacteria and methods for treating or preventing an irradiation-induced intestinal damage in a subject, the methods comprising administering a G1 bacterium to the subject, wherein the G1 bacterium comprises a vector that comprises a polynucleotide encoding IL-22 and/or IFN-P, or a functional fragment thereof.